Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 74   

Articles published

CBST 61.40 -1.11 (-1.78%)
price chart
Analyst Update: EMC Corporation, Teva Pharmaceutical Industries Ltd (ADR ...
Meanwhile, among the equities in focus are tech issue EMC Corporation (NYSE:EMC), as well as drug makers Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Cubist Pharmaceuticals Inc (NASDAQ:CBST), which have all attracted analyst ...
Cubist Pharmaceuticals Inc.: Cubist Reports Second Quarter 2014 Financial ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the second quarter ended June 30, 2014.
JMP Securities Downgrades Cubist Pharmaceuticals to Market Perform (CBST)  Intercooler
Cubist Reports Second Quarter 2014 Financial Results  Wall Street Journal
Related articles »  
Cubist Pharmaceuticals Rating Lowered to Market Perform at JMP Securities ...
Cubist Pharmaceuticals Inc logo Cubist Pharmaceuticals (NASDAQ:CBST) was downgraded by research analysts at JMP Securities from an �outperform� rating to a �market perform� rating in a report released on Wednesday, TheFlyOnTheWall.
Cubist Pharmaceuticals Lowered to Market Perform at JMP Securities (CBST)
Cubist Pharmaceuticals Inc logo JMP Securities cut shares of Cubist Pharmaceuticals (NASDAQ:CBST) from an outperform rating to a market perform rating in a research note issued to investors on Wednesday, TheFlyOnTheWall.
Active Biotech Stocks in Concerns- MannKind Corporation (NASDAQ:MNKD ...
Cubist Pharmaceuticals Inc (NASDAQ:CBST) [Trend Analysis] has second quarter 2014 earnings (excluding special items) of 23 cents per share dropped well short of the Zacks Consensus anticipates of 37 cents due to lesser than anticipated revenues.
Related articles »  
Cubist Pharmaceuticals (CBST) Posts Quarterly Earnings Results, Beats ...
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) posted its quarterly earnings results on Tuesday. The company reported $0.23 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.01 by $0.22, AnalystRatings.
Hot Stocks - Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), MannKind. (NASDAQ ...
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) second quarter 2014 earnings (excluding special items) of 23 cents per share fell well short of the Zacks Consensus Estimate of 37 cents due to lower-than-expected revenues.
Cubist Pharmaceuticals (CBST) Scheduled to Post Earnings on Tuesday
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in ...
Cubist to Present at August Investor Conference
LEXINGTON, Mass., Jul 28, 2014 (BUSINESS WIRE) -- Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that company management will discuss Cubist's business activities and financial outlook at investor conferences during August 2013.
Related articles »  
Why Questcor Pharmaceuticals Inc(NASDAQ:QCOR) Shares Attracts Investors ...
Cubist Pharmaceuticals' (NASDAQ:CBST) second quarter 2014 earnings (omitting special items) of 23 cents per share declined way too short of the Zacks Consensus Estimate of 37 cents because of lower-than-predicted revenues.